Company Overview and News
* CANCER GENETICS RECEIVES NON-DILUTIVE FUNDING OF $1.1 MILLION THROUGH NEW JERSEY TECHNOLOGY BUSINESS TAX CERTIFICATE TRANSFER (NOL) PROGRAM (1-0)
LONDON, UK / ACCESSWIRE / December 13, 2017 / Active-Investors issued a free report on Cancer Genetics, Inc. (NASDAQ: CGIX), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=CGIX as the Company's latest news hit the wire. On December 11, 2017, the Company announced results of a study indicating the potential value of being platform-agnostic and choosing the best diagnostic modality to evaluate an important molecular biomarker, PD-L1, in Diffuse Large B-Cell Lymphomas (DLBCL). (3-0)
* CANCER GENETICS INC - PRICING OF A REGISTERED DIRECT OFFERING OF 3.5 MILLION UNITS AT $2.00 PER UNIT Source text for Eikon: Further company coverage: (1-0)
NEW YORK, NY / ACCESSWIRE / December 4, 2017 / PCG Advisory Group (PCG), a leading, New York City-based investor relations and digital strategies firm, announced today that Jeff Ramson, Founder and CEO, will be sitting on the "How Blockchains Will Revolutionize Our Daily Lives" panel at the 10th Annual LD Micro Main Event, taking place on December 5th -7th, at the Luxe Sunset Bel Air Hotel, Los Angeles, CA. (7-0)
Good morning, and welcome to the Cancer Genetics Third Quarter 2017 Earnings Call and Company Update. This morning, the company issued a press release that provided an overview of the third quarter and nine months 2017 results. Today's conference is being recorded and will be available at investors.cgix.com. Additionally, CGIX has also provided a set of slides to accompany today's update that are available both online or by contacting ir@cgix. (1-0)
BOCA RATON, FL / ACCESSWIRE / October 10, 2017 / Dawson James Securities, Inc. is hosting its 3rd Annual Small Cap Growth Conference on October 18th and 19th at the Wyndham Grand Jupiter at Harbourside Place, Jupiter, Florida. More than 32 public companies are expected to present to an audience of over 250 attendees, including high net worth investors, family offices, and small cap focused institutional funds. (6-0)
The "Medical Laboratory Testing Services including Cardiac, Molecular Diagnostic and Genomic. Strategies & Trends. Price & Volume Forecasts by Laboratory Department by Country. 2017 to 2022 - Global Version" report has been added to Research and Markets' offering. (75-1)
The "Clinical Laboratory, Cardiac, Molecular Diagnostics and Genomic Testing Services. Strategies & Trends. Volume & Price Forecasts by Laboratory Department by Country. 2017 to 2022 - Global Version" report has been added to Research and Markets' offering. (87-1)
The "In Vitro Diagnostic Testing Services including Cardiac, Molecular Diagnostic and Genomic. Strategies & Trends. Price & Volume Forecasts by Laboratory Department by Country. 2017 to 2022 - Global Version" report has been added to Research and Markets' offering. (87-1)
RUTHERFORD, N.J. and LOS ANGELES, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (“CGI” or the “Company”) (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today it has closed its 25th contract to support a drug combination trial for immuno-oncology agents. (88-0)
RUTHERFORD, N.J. and LOS ANGELES, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (The Company and CGI), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will host an investor and analyst call and webcast on Tuesday, August 22, 2017 at 8:30 am Eastern. CGI will discuss the strategy and business rationale of the recent transformative and accretive acquisition of vivoPharm.
Cancer Genetics (CGI) is buying cancer drug discovery and preclinical services company vivoPharm, for $12 million in cash and shares. CGI said it expects the acquisition to strengthen its position as a provider of services for oncology discovery, in vivo and in vitro drug development and early phase clinical trials testing, and expand its presence in Europe and Australia. The acquisition, which has been approved by both companies’ boards, is projected to close today.
RUTHERFORD, N.J. and MELBOURNE, Australia, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“CGI” or “the Company”) and vivoPharm Pty. Ltd. (“vivoPharm”) announced today they have entered into a definitive agreement for Cancer Genetics to acquire vivoPharm for approximately $12 million USD. This transaction will significantly strengthen CGI's position as a premier leader for oncology discovery, in vivo and in vitro drug development and early phase clinical trial testing for biotechnology and pharmaceutical companies.
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton